A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

288

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

August 29, 2025

Study Completion Date

September 25, 2025

Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
DRUG

Brensocatib

Film-coated tablet.

DRUG

Placebo

Film-coated tablet.

DRUG

Mometasone furoate nasal spray (MFNS)

Nasal spray suspension.

Trial Locations (100)

1200

BEL003, Woluwe-Saint-Lambert

1606

BGR005, Sofia

2100

DNK001, København Ø

3000

ARG008, Santa Fe

3400

DNK004, Hillerød

4001

BGR003, Plovdiv

4029

AUS001, Herston

4600

DNK002, Køge

4710

PRT002, Braga

5101

BEL002, Erpent

5500

ARG014, Mendoza

6000

BGR006, Stara Zagora

6163

AUS002, Spearwood

7621

HUN003, Pécs

8000

DNK003, Aarhus C

9000

BEL001, Ghent

10016

USA033, New York

10117

GER007, Berlin

11407

ESP002, Jerez de la Frontera

13010

FRA003, Marseille

17033

USA015, Hershey

20089

ITA001, Rozzano

21287

USA026, Baltimore

23507

USA005, Norfolk

23562

GER008, Lübeck

29009

ESP004, Málaga

29406

USA022, North Charleston

29425

USA023, Charleston

33024

USA019, Hollywood

33135

USA001, Miami

33487

USA016, Boca Raton

33613

USA009, Tampa

39008

ESP003, Santander

41009

ESP001, Seville

44000

FRA001, Nantes

47150

USA003, New Albany

56124

ITA003, Pisa

60611

USA031, Chicago

60612

USA021, Chicago

63141

USA024, St Louis

65183

GER004, Wiesbaden

65212

USA011, Columbia

67200

FRA002, Strasbourg

70471

USA035, Mandeville

74132

USA028, Tulsa

74136

USA004, Tulsa

75231

USA025, Dallas

77022

USA029, Houston

77030

USA018, Houston

77375

USA038, Tomball

78258

USA030, San Antonio

78624

USA037, Fredericksburg

85704

USA034, Tucson

85925

FRA004, La Roche-sur-Yon

91786

USA006, Upland

95661

USA002, Roseville

B1900BNN

ARG015, La Plata

B1900

ARG001, La Plata

B7240AAN

ARG006, Lobos

C1121ABE

ARG005, Buenos Aires

C1414

ARG012, Buenos Aires

C1425

ARG011, Buenos Aires

C1426ABP

ARG017, Buenos Aires

M5600IBJ

ARG013, San Rafael

S2013DBS

ARG007, Rosario

S2013DTC

ARG010, Rosario

S2013

ARG004, Rosario

T4000AXL

ARG009, San Miguel de Tucumán

B7602DCK

ARG002, Mar del Plata

M5500CCG

ARG003, Mendoza

S2002KDT

ARG016, Rosario

V6Z 1Y6

CAN003, Vancouver

N6A 4V2

CAN006, London

M5G 1X5

CAN007, Toronto

H4A 3J1

CAN005, Montreal

G1S 4L8

CAN001, Québec

G1V 4W2

CAN002, Québec

779 00

CZE002, Olomouc

532 03

CZE003, Pardubice

500 05

CZE005, Nový Hradec Králové

140 59

CZE004, Prague

04103

GER009, Leipzig

09648

GER003, Mittweida

07747

GER005, Jena

01307

GER001, Dresden

07100

ITA002, Sassari

60-309

POL002, Poznan

60-693

POL010, Poznan

30-033

POL005, Krakow

32-020

POL007, Wieliczka

52-416

POL009, Wroclaw

20-954

POL003, Lublin

00-189

POL001, Warsaw

15-276

POL004, Bialystok

40-611

POL006, Katowice

04-141

POL008, Warsaw

4835-044

PRT001, Guimarães

1349-019

PRT003, Lisbon

4464-513

PRT005, Senhora da Hora

3814-501

PRT004, Aveiro

All Listed Sponsors
lead

Insmed Incorporated

INDUSTRY

NCT06013241 - A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) | Biotech Hunter | Biotech Hunter